NCT06096896Active, not recruiting
The Efficacy and Safety of EOB-MRI Guided Microwave Ablation for Early HCC: A Multicenter, Prospective, Observational Study
Source: ClinicalTrials.gov · Last updated 24 Oct 2023
Brief summary (registry, in English)
HCC is one of most common causes of cancer-related death in the world due to lately diagnosis by typical hallmarks which rely on completed arterialization. So it is important to earlier diagnose and treat hypovascular early HCC(eHCC). The aim of this study is to evaluate the efficacy and safety of microwave ablation for early HCC, also to explore the feasibility of EOB-MRI (Gd-EOB-DTPA enhanced MRI) guided ablation.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 334 (estimated)
- First submitted
- 17 Oct 2023
- Start date
- 30 Aug 2023
- Primary completion date
- 30 Sept 2025
- Lead sponsor
- Shandong Provincial Hospital
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT06096896
What you commit to
- Study type: Observational
- Planned participants: 334
- From 30 Aug 2023 to the primary completion date, 30 Sept 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Prior malignancy;
Lab values
- Suffering from uncorrectable coagulation dysfunction (prothrombin time \> 25 seconds, prothrombin activity \< 40%, platelet count ≤ 50x10\^9/L);
Other
- Presence of lymph nodes or distant metastases;
- Presence of liver metastases;
- Severe cardiopulmonary or renal dysfunction;
- Severe infectious lesions in the area of the puncture needle tract.
Who the study is looking for
- Age ≥ 18 years;
- Patients with chronic liver disease who are at high/extremely high-risk of hepatocellular carcinoma;
- EOB-MRI suggestive of confirmed or suspected eHCC (single lesion ≤ 2 cm or number of lesions ≤ 3 and maximum diameter ≤ 2 cm)
- No previous history of hepatocellular carcinoma;
- Not receiving any anti-cancer treatment;
- Liver function Child-push A or B.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shandong PH Coordinator of this site? Confirm its status | Jinan | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.